Corylin

Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways^[1][2][3]. In Vitro: Corylin (3-300 µM, 0-72 h) inhibits the proliferation of HepG2 and Huh7 cells^[2].
Corylin (3-30 µM, 0-48 h) inhibits the migration and invasiveness of HepG2 and Huh7 cells by suppressing EMT^[2].
Corylin (5-200 µM, 24 h) reduces the viability of 3T3-L1 preadipocytes at the doses of 100-200 µM^[3].
Corylin (10 µM, 24 h) induces browning via the SIRT1 and β3-AR pathways in 3T3-L1 adipocytes^[3].
In Vivo: Corylin (60 mg/kg, i.p., three times a week, 4 weeks) inhibits tumor growth in Huh7 cells xenograft mice^[3].
Corylin (50-100 mg/kg, p.o., daily, 9 weeks) improves the high-fat diet (HFD)-induced obesity in HFD- and DIO-treated mice^[3].